10-Q: Veru Inc. Reports Positive Topline Results from Phase 2b Obesity Trial and Announces Sale of FC2 Business in Q1 2025

Veru Inc. announces positive Phase 2b clinical trial results for enobosarm in obesity treatment and the sale of its FC2 business, impacting financial results for the quarter ended December 31, 2024.

Summary

• Veru Inc. reported a net loss of $8.9 million for the quarter ended December 31, 2024.
• The company announced positive topline results from its Phase 2b QUALITY clinical trial for enobosarm in treating obesity, showing a statistically significant preservation of lean body mass.
• Veru completed the sale of its FC2 business on December 30, 2024, for $18.0 million, resulting in net proceeds of approximately $16.4 million and a loss on sale of $4.2 million.
• Research and development expenses increased to $5.7 million due to the ongoing Phase 2b QUALITY clinical trial.
• The company recognized a gain on extinguishment of debt of $8.6 million related to the termination of the Residual Royalty Agreement in connection with the FC2 Business Sale.
• Veru is planning to request an end of Phase 2 meeting with the FDA and is developing a novel modified release oral formulation for enobosarm.
• The company is exploring the clinical development of sabizabulin for the treatment of inflammation in atherosclerotic cardiovascular disease and had a pre-IND meeting with the FDA on December 26, 2024.
• Veru's cash, cash equivalents, and restricted cash totaled $26.6 million as of December 31, 2024.
• The company acknowledges substantial doubt about its ability to continue as a going concern for the next twelve months without additional funding.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. Positive clinical trial results are offset by financial losses, going concern uncertainty, and regulatory hurdles.

Positives

• Positive topline results from the Phase 2b QUALITY clinical trial for enobosarm in obesity treatment were achieved.
• The sale of the FC2 business generated net proceeds of approximately $16.4 million.
• The company recognized a gain on extinguishment of debt of $8.6 million.
• The FDA agreed with the general design of the small Phase 2 study using coronary CT angiography imaging as primary endpoint for sabizabulin to slow progression or promote regression of atherosclerotic disease in patients with a history of coronary artery disease.

Negatives

• Veru Inc. reported a net loss of $8.9 million for the quarter ended December 31, 2024.
• The sale of the FC2 business resulted in a loss on sale of $4.2 million.
• The company acknowledges substantial doubt about its ability to continue as a going concern for the next twelve months without additional funding.
• The company is ineligible to file new registration statements on Form S-3 or to use its current effective shelf registration statement on Form S-3 until March 1, 2025, which may impair its ability to raise capital.

Risks

• The company's future success depends on obtaining regulatory approval and successfully commercializing its drug candidates.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company is ineligible to use Form S-3 for capital raising until March 1, 2025.
• There is uncertainty regarding additional payments from ONCO related to the sale of ENTADFI assets.
• The company faces competition in the pharmaceutical industry.
• The company may be subject to claims or investigations relating to The Pill Clubs business practices with respect to sales of FC2.
• The company is subject to significant payment obligations pursuant to the resolution of a dispute with a supplier.
• The company has been named a defendant in stockholder class actions.
• The company may be unable to protect the proprietary nature of the intellectual property covering its products.
• The company has received a notice of delisting from Nasdaq.

Future Outlook

The company plans to request an end of Phase 2 meeting with the FDA for enobosarm in obesity treatment and is developing a novel modified release oral formulation. It is also exploring the clinical development of sabizabulin for atherosclerotic cardiovascular disease, with a potential Phase 2 clinical study planned.

Management Comments

• The Phase 2b QUALITY study is the first human study to report the effects of a muscle preservation drug candidate on body composition in older patients who have obesity or are overweight and receiving a GLP-1 receptor agonist.
• Enobosarm represents a next generation drug that improves GLP-1 RA therapy to result in tissue selective quality weight reduction, that is, enobosarm + semaglutide improved changes in body composition which resulted in more selective and greater loss of adiposity (fat mass) than in subjects receiving placebo + semaglutide alone.

Industry Context

The announcement highlights the growing interest in treatments for obesity and related conditions, particularly those that address muscle loss associated with GLP-1 RA therapies. The company is also exploring the clinical development of sabizabulin for the treatment of inflammation in atherosclerotic cardiovascular disease, which is a significant unmet medical need.

Comparison to Industry Standards

• The document references third-party clinical trials evaluating GLP-1 RA in obese patients, noting that 20-50% of the total weight loss was attributable to lean mass loss.
• The document references recent randomized controlled trials assessing the role of low-dose colchicine to treat inflammation to reduce major adverse cardiovascular events (MACE), including COLCOT (Efficacy and Safety of Low-Dose colchicine after Myocardial Infarction), LoDoCo (Low-dose colchicine for secondary prevention of cardiovascular disease) and LoDoCo-2 (Colchicine in Patients with Chronic Coronary Disease) trials, had promising results demonstrating significant cardiovascular risk reduction.
• The document references Vaidya et al. (2018) conducted a prospective open label single center clinical study to evaluate the effects of colchicine on modifying the atheromatous coronary artery plaques by coronary CT angiography (CCTA) imaging.
• The document references the SCOT-HEART Trial (Scottish Computed Tomography of the HEART).

Legal Proceedings

• The company is involved in several shareholder litigation cases related to public statements about sabizabulin as a treatment for COVID-19.
• The company is unable to estimate potential losses, if any, related to the Shareholder Litigation.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by potential cost-cutting measures or changes in strategic direction.
• Patients could benefit from successful development and commercialization of new treatments.
• The sale of the FC2 business may impact suppliers and customers of that business.

Next Steps

• The company plans to request an end of Phase 2 meeting with the FDA for enobosarm in obesity treatment.
• The company plans to present the full clinical efficacy and safety data set for the Phase 2b QUALITY clinical study in future scientific conferences and publications after the Phase 2b extension portion of study is completed and unblinded.
• The company is developing a novel modified release oral formulation for enobosarm with a Phase 1 bioavailability clinical trial anticipated during the first half of 2025.
• The company plans to submit a new IND for sabizabulin as a treatment to slow progression or promote regression of atherosclerotic disease by the first half of calendar 2026.

Key Dates

Keywords

enobosarm, sabizabulin, FC2 business sale, clinical trial, obesity, atherosclerosis, financial results, Veru Inc., FDA, net loss